Lycopene ameliorates hyperlipidemia via potentiation of AMP-activated protein kinase and inhibition of ATP-citrate lyase in diabetic hyperlipidemic rat model

Lycopene ameliorates islet function and down-regulates the TLR4/MyD88/NF-κB pathway in diabetic mice and Min6 cells

“…The exposure of mice to HFD/STZ may cause hyperglycemia and dyslipidemia, and these alterations were prevented by lycopene intervention, including an improvement in glucose tolerance, FBG levels, calorie and water intake, and body composition, as well as blood lipid profiles (TC, TG, LDL, and HDL), which is consistent with the previous reports that lycopene attenuates glucose and lipid disorders in HFD-induced obese rats 27,28 and STZ-CCT (4% cholesterol, 1% cholic acid in diet and 0.5% thiouracil in drinking water) diet-induced hyperglycemia and hyperlipidemic rats. 49 Epidemiological investigations also indicate that lycopene consumption may deliver benefits for glucose and lipid metabolism. 22 However, in the present study, we found that mice in the NC group consumed fewer calories but were heavier than those in the DM group.…”

Physicochemical properties, mechanism of action of lycopene and its application in poultry and ruminant production

“…Moreover, lycopene enhanced the activity of AMP-activated protein kinase ( AMPK-P ) and downregulating ATP citrate-raising lyase ( ACLY ). Ultimately, the levels of MDA, HMG-CoA reductase , FAS , ACLY , and TNF-α were reduced and the levels of AMPK-P and GSH were increased in diabetic hyperlipidemia rats ( 75 ).…”